Back to Browse Journals » ClinicoEconomics and Outcomes Research » Volume 4

Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate

Authors Vaidya V, Patel P

Published Date February 2012 Volume 2012:4 Pages 49—56

DOI http://dx.doi.org/10.2147/CEOR.S27609

Received 24 October 2011, Accepted 29 November 2011, Published 7 February 2012

Varun Vaidya, Pranav Patel
College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA

Background: Metoprolol, a selective beta-1 blocker, is available in two different salt forms in the market – metoprolol succinate (MS) and metoprolol tartarate (MT). Both the formulations are Food and Drug Administration approved for the treatment of hypertension. Several studies have shown similar efficacies between the two salts; however, they differ in their pharmacokinetic properties and are therefore priced differently. The primary objective of this study was to compare the overall health care expenditures of hypertensive patients on MT and MS to see if the price difference in the two preparations is offset by savings in overall expenditure.
Methods: Two cohorts of patients using MT and MS were selected from the 2008 Medical Expenditure Panel Survey. Propensity score matching technique was used to balance the cohorts on various parameters such as demographic information, insurance status, and comorbidity score. Patients using MT were matched to patients using MS on the logit of propensity score using calipers of width equal to 0.2 of the standard deviation of the logit of the propensity score. Multiple regression analysis was carried out to examine the association between health expenditure and type of metoprolol salt, adjusting for other covariates.
Results: A total of 742 patients were found to use metoprolol (MT-388, MS-354). After propensity score matching, a total of 582 patients were left in the sample for final analysis (291 patients in each cohort). The average annual health care expenditure was slightly higher in the MT cohort; however, after adjusting for covariates in a multivariate analysis, the difference was found to be statistically insignificant (P = 0.23).
Conclusion: Both the products of metoprolol were found to have similar average annual total health care expenditure; however, MS once a day has higher out-of-pocket cost.

Keywords: hypertension, cost, propensity score

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Demographic disparities in patient-reported use of inhaled corticosteroids among patients with persistent asthma

Varun Vaidya, Monica Holiday-Goodman, Sharrel Pinto

Journal of Asthma and Allergy 2010, 3:101-106

Published Date: 24 August 2010

Utilization of preventive care services and their effect on cardiovascular outcomes in the United States

Varun Vaidya, Gautam Partha, Jennifer Howe

Risk Management and Healthcare Policy 2011, 4:1-7

Published Date: 19 January 2011

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Inpatient charges and mental illness: Findings from the Nationwide Inpatient Sample 1999–2007

Jim E Banta, Ivorie Belk, Kedon Newton, et al

ClinicoEconomics and Outcomes Research 2010, 2:149-158

Published Date: 11 October 2010

The role of galenic innovation in improving treatment compliance and persistence: three case studies

Zoellner Y, Balp MM, Gili Marco A

ClinicoEconomics and Outcomes Research 2011, 3:109-116

Published Date: 4 August 2011

Impact of dry eye on work productivity

Yamada M, Mizuno Y, Shigeyasu C

ClinicoEconomics and Outcomes Research 2012, 4:307-312

Published Date: 10 October 2012

Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy

Nadkarni A, Kalsekar I, You M, Forbes R, Hebden T

ClinicoEconomics and Outcomes Research 2013, 5:49-57

Published Date: 20 January 2013

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases

Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E

ClinicoEconomics and Outcomes Research 2013, 5:193-201

Published Date: 14 May 2013